JP2017503862A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503862A5 JP2017503862A5 JP2016563897A JP2016563897A JP2017503862A5 JP 2017503862 A5 JP2017503862 A5 JP 2017503862A5 JP 2016563897 A JP2016563897 A JP 2016563897A JP 2016563897 A JP2016563897 A JP 2016563897A JP 2017503862 A5 JP2017503862 A5 JP 2017503862A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- residues
- polypeptide
- compound
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 229960002707 bendamustine Drugs 0.000 claims 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 2
- 229960004630 chlorambucil Drugs 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 101150039808 Egfr gene Proteins 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 101100066427 Homo sapiens FCGR1A gene Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461926386P | 2014-01-12 | 2014-01-12 | |
| US61/926,386 | 2014-01-12 | ||
| PCT/US2015/011066 WO2015106224A2 (en) | 2014-01-12 | 2015-01-12 | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503862A JP2017503862A (ja) | 2017-02-02 |
| JP2017503862A5 true JP2017503862A5 (enExample) | 2018-02-22 |
| JP6835590B2 JP6835590B2 (ja) | 2021-02-24 |
Family
ID=53520421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563897A Active JP6835590B2 (ja) | 2014-01-12 | 2015-01-12 | インスリン様成長因子−１および上皮増殖因子を含む融合タンパク質およびそのバリアントならびにその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9675671B2 (enExample) |
| EP (1) | EP3094339B1 (enExample) |
| JP (1) | JP6835590B2 (enExample) |
| AU (1) | AU2015204540B2 (enExample) |
| CA (1) | CA2936675C (enExample) |
| WO (1) | WO2015106224A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2800173C (en) | 2010-05-21 | 2019-05-14 | Ulrik Nielsen | Bi-specific fusion proteins |
| US10040840B2 (en) | 2015-10-02 | 2018-08-07 | Silver Creek Pharmaceuticals, Inc. | Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue |
| KR101678392B1 (ko) * | 2016-09-30 | 2016-11-22 | (주)넥스젠바이오텍 | 항산화 기능 및 피부 세포 증식 효과가 증가된 부동화 단백질 및 인간 상피세포성장인자를 포함하는 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물 |
| EP3630195A4 (en) * | 2017-05-21 | 2021-03-24 | IGF Oncology, LLC | INSULIN-LIKE GROWTH FACTOR CONJUGATE - CHEMOTHERAPEUTIC PRODUCT FOR THE TREATMENT OF MYELODYSPLASIC SYNDROME |
| US12222354B2 (en) * | 2021-03-19 | 2025-02-11 | Quest Diagnostics Investments Llc | Identification and quantitation of insulin-like growth factor-I variants by mass spectrometry |
| AU2023417644A1 (en) * | 2022-12-30 | 2025-07-31 | Lg Chem, Ltd. | Recombinant fusion protein having modified cysteine residue for antigen delivery and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62175182A (ja) * | 1985-10-21 | 1987-07-31 | Takeda Chem Ind Ltd | 動物細胞用発現ベクタ−およびその用途 |
| AU1799588A (en) | 1987-05-11 | 1988-12-06 | Procyte Corporation | Method of tumor inhibition in warm-blooded animals |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US4876242A (en) | 1987-09-21 | 1989-10-24 | Merck & Co., Inc. | Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast |
| FI890312A7 (fi) * | 1988-01-25 | 1989-07-26 | Oncogen | Amfireguliini: uusi bifunktionaalinen kasvua moduloiva glykoproteiini |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| CA2016584C (en) | 1989-05-17 | 1999-06-29 | Robert S. Greenfield | Anthracycline conjugates having a novel linker and methods for their production |
| US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US5158875A (en) * | 1989-08-25 | 1992-10-27 | Amgen Inc. | Production of biologically active insulin-like growth factor i from high expression host cell systems |
| US5886141A (en) * | 1990-10-26 | 1999-03-23 | Takeda Chemical Industries, Ltd. | Smooth muscle mitogen peptides and DNA coding therefor |
| WO1993021939A1 (en) | 1992-04-27 | 1993-11-11 | New England Deaconess Hospital Corporation | Method of treating cancer |
| US5444045A (en) | 1992-09-17 | 1995-08-22 | Gropep, Pty. Ltd. | Method of administering IGF-1, IGF-2, and analogs thereof to birds |
| US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US5728676A (en) * | 1994-09-08 | 1998-03-17 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
| AU4317399A (en) * | 1998-05-28 | 1999-12-13 | Parker Hughes Institute | Quinazolines for treating brain tumor |
| US7173005B2 (en) | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
| JP4751556B2 (ja) | 2000-02-28 | 2011-08-17 | ジーンシーグス， インコーポレイテッド | ナノカプセルカプセル化システムおよび方法 |
| IL153288A0 (en) | 2000-06-07 | 2003-07-06 | Applied Research Systems | Use of growth hormone or a derivative thereof in the preparation of a medicament for hematopoiesis |
| WO2002049672A2 (en) | 2000-12-21 | 2002-06-27 | Mcgill University | Conjugates of antibodies and anticancer drugs |
| JP2004531217A (ja) | 2001-01-05 | 2004-10-14 | ファイザー・インク | インスリン様成長因子ｉ受容体に対する抗体 |
| CA2702192A1 (en) | 2001-03-14 | 2002-09-19 | Genentech, Inc. | Igf antagonist peptides |
| EP1610751A4 (en) | 2001-04-26 | 2006-05-24 | Univ Texas | THERAPEUTIC AGENT / LIGAND CONJUGATE COMPOSITIONS, ITS SYNTHESIS PROCESSES AND ITS APPLICATION |
| JP2003009883A (ja) * | 2001-07-05 | 2003-01-14 | Mitsubishi Pharma Corp | マスト細胞の細胞死誘発剤 |
| CA2465724A1 (en) * | 2001-11-05 | 2003-05-15 | Research Development Foundation | Engineering of leader peptides for the secretion of recombinant proteins in bacteria |
| US7419783B2 (en) * | 2001-11-05 | 2008-09-02 | Research Development Foundation | Engineering of leader peptides for the secretion of recombinant proteins in bacteria |
| JP4477881B2 (ja) | 2002-03-01 | 2010-06-09 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | 治療剤または細胞毒性剤と生物活性ペプチドとの抱合体 |
| US20040038303A1 (en) | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| US20040142381A1 (en) | 2002-07-31 | 2004-07-22 | Hubbard Stevan R. | Methods for designing IGF1 receptor modulators for therapeutics |
| US20030138430A1 (en) | 2002-09-20 | 2003-07-24 | Stimmel Julie Beth | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
| CA2542834C (en) * | 2003-10-21 | 2012-04-24 | Igf Oncology, Llc | Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents |
| EP1557429A1 (en) * | 2004-01-23 | 2005-07-27 | Vectron Therapeutics AG | Site-directed coupling of proteins |
| WO2005072292A2 (en) * | 2004-01-24 | 2005-08-11 | Hugh Mctavish | Methods for enhancing radiation therapy |
| JP2008517917A (ja) * | 2004-10-21 | 2008-05-29 | アイジーエフ オンコロジー エルエルシー | 癌を治療するための毒素および放射性核種結合ｉｇｆ−１受容体リガンド |
| US20100226884A1 (en) * | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| ES2393373T3 (es) * | 2006-08-31 | 2012-12-20 | F. Hoffmann-La Roche Ag | Método para la producción de factor-I de crecimiento similar a la insulina |
| WO2009030720A2 (en) * | 2007-09-06 | 2009-03-12 | Novozymes Biopharma Dk A/S | Process for producing a recombinant protein |
| WO2010042821A1 (en) * | 2008-10-10 | 2010-04-15 | Nationwide Children's Hospital | Method of treating necrotizing enterocolitis using heparin binding epidermal growth factor |
| US20100197890A1 (en) * | 2009-01-31 | 2010-08-05 | Mctavish Hugh | Anti-cancer protein-platinum conjugates |
| US8986956B2 (en) * | 2010-11-04 | 2015-03-24 | Korea Research Institute Of Bioscience And Biotechnology | Method for producing human epidermal growth factor in large volume from yeast |
| US20160122411A1 (en) * | 2013-03-29 | 2016-05-05 | Merrimack Pharmaceuticals, Inc. | Cartilage-binding fusion proteins |
-
2015
- 2015-01-12 AU AU2015204540A patent/AU2015204540B2/en active Active
- 2015-01-12 US US14/594,980 patent/US9675671B2/en active Active
- 2015-01-12 CA CA2936675A patent/CA2936675C/en active Active
- 2015-01-12 WO PCT/US2015/011066 patent/WO2015106224A2/en not_active Ceased
- 2015-01-12 JP JP2016563897A patent/JP6835590B2/ja active Active
- 2015-01-12 EP EP15734843.4A patent/EP3094339B1/en active Active
-
2017
- 2017-05-29 US US15/607,581 patent/US9801923B2/en active Active
- 2017-10-08 US US15/727,621 patent/US10391147B2/en active Active
-
2019
- 2019-07-23 US US16/520,179 patent/US10967049B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503862A5 (enExample) | ||
| JP2018503668A5 (enExample) | ||
| JP2014193892A5 (enExample) | ||
| CY1123788T1 (el) | Αντισωματα αντι-ακτιβινης α και χρησεις αυτων | |
| NZ731185A (en) | Bicyclic peptide ligands specific for mt1-mmp | |
| JP2013172734A5 (enExample) | ||
| CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
| PH12017500915A1 (en) | Cd47 antibodies, methods, and uses | |
| MX2012000765A (es) | Dominios variables sencillos de union de albumina anti-suero mejorados. | |
| MX2018006243A (es) | Proteinas de union a pd1/ctla4. | |
| JP2015164127A5 (enExample) | ||
| JP2016531927A5 (enExample) | ||
| HRP20231570T1 (hr) | Peptid za uporabu u imunoterapiji protiv nesitnostaničnog raka pluća i sitnostaničnog raka pluća | |
| HK1200842A1 (en) | Proteins with improved half-life and other properties | |
| JP2014129395A5 (enExample) | ||
| WO2015156870A3 (en) | Biopolymer-mediated assembly of nanoparticles using genetically encoded proteins | |
| JP2014138100A5 (enExample) | ||
| JP2018504907A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| WO2015197598A3 (en) | Multispecific antigen binding proteins | |
| JP2013539454A5 (enExample) | ||
| MX2016000381A (es) | Particula tipo virus que comprende antigeno de muerte celular programada 1 o antigeno de ligando de muerte celular programada 1. | |
| CA2872308A1 (en) | Novel ha binding agents | |
| JP2016502515A5 (enExample) | ||
| MX2018013342A (es) | Polipeptido de fusion multicircular "contorsbody" - ligante de diana de cadena sencilla. |